2,150 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Skylands Capital LLC

Skylands Capital LLC acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,150 shares of the medical research company’s stock, valued at approximately $694,000.

A number of other hedge funds have also recently added to or reduced their stakes in BIO. Brown Advisory Inc. boosted its holdings in shares of Bio-Rad Laboratories by 3.1% during the 3rd quarter. Brown Advisory Inc. now owns 955,732 shares of the medical research company’s stock valued at $342,582,000 after acquiring an additional 28,724 shares in the last quarter. Earnest Partners LLC boosted its stake in shares of Bio-Rad Laboratories by 25.6% during the third quarter. Earnest Partners LLC now owns 351,510 shares of the medical research company’s stock valued at $125,999,000 after purchasing an additional 71,570 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Bio-Rad Laboratories by 8.0% during the third quarter. Invesco Ltd. now owns 343,462 shares of the medical research company’s stock worth $123,114,000 after purchasing an additional 25,562 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of Bio-Rad Laboratories in the third quarter valued at approximately $116,036,000. Finally, Thompson Siegel & Walmsley LLC raised its holdings in Bio-Rad Laboratories by 6.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 312,583 shares of the medical research company’s stock valued at $112,046,000 after buying an additional 18,419 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 0.4 %

Shares of NYSE:BIO opened at $277.11 on Tuesday. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $473.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34. The business’s 50-day moving average is $323.67 and its 200-day moving average is $316.47.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.17. The firm had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company’s revenue was down 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.31 earnings per share. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Insider Activity at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the transaction, the executive vice president now owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 17.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have weighed in on BIO. UBS Group boosted their target price on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada decreased their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a report on Friday, February 16th. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Finally, Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus target price of $468.00.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.